Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to 0.76.

  • Cytek Biosciences' Equity Ratio fell 252.08% to 0.76 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.76, marking a year-over-year decrease of 252.08%. This contributed to the annual value of 0.79 for FY2024, which is 33.64% down from last year.
  • Cytek Biosciences' Equity Ratio amounted to 0.76 in Q3 2025, which was down 252.08% from 0.77 recorded in Q2 2025.
  • Cytek Biosciences' Equity Ratio's 5-year high stood at 0.89 during Q3 2021, with a 5-year trough of 0.05 in Q2 2021.
  • For the 5-year period, Cytek Biosciences' Equity Ratio averaged around 0.76, with its median value being 0.8 (2024).
  • Over the last 5 years, Cytek Biosciences' Equity Ratio had its largest YoY gain of 184882.64% in 2022, and its largest YoY loss of 637.75% in 2022.
  • Quarter analysis of 5 years shows Cytek Biosciences' Equity Ratio stood at 0.87 in 2021, then fell by 6.38% to 0.82 in 2022, then decreased by 2.96% to 0.79 in 2023, then dropped by 0.34% to 0.79 in 2024, then dropped by 3.45% to 0.76 in 2025.
  • Its last three reported values are 0.76 in Q3 2025, 0.77 for Q2 2025, and 0.79 during Q1 2025.